EyePoint (PV3B) Stock Overview
Engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PV3B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
EyePoint, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.13 |
| 52 Week High | US$15.32 |
| 52 Week Low | US$3.53 |
| Beta | 1.69 |
| 1 Month Change | 31.68% |
| 3 Month Change | 32.78% |
| 1 Year Change | 98.50% |
| 3 Year Change | 391.23% |
| 5 Year Change | 78.42% |
| Change since IPO | -34.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| PV3B | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.2% | 2.2% | 0.7% |
| 1Y | 98.5% | 11.3% | 14.2% |
Return vs Industry: PV3B exceeded the German Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: PV3B exceeded the German Market which returned 14.2% over the past year.
Price Volatility
| PV3B volatility | |
|---|---|
| PV3B Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: PV3B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PV3B's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 165 | Jay Duker | eyepoint.bio |
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
EyePoint, Inc. Fundamentals Summary
| PV3B fundamental statistics | |
|---|---|
| Market cap | €1.29b |
| Earnings (TTM) | -€175.18m |
| Revenue (TTM) | €36.05m |
Is PV3B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PV3B income statement (TTM) | |
|---|---|
| Revenue | US$42.34m |
| Cost of Revenue | US$203.76m |
| Gross Profit | -US$161.42m |
| Other Expenses | US$44.34m |
| Earnings | -US$205.75m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.49 |
| Gross Margin | -381.25% |
| Net Profit Margin | -485.96% |
| Debt/Equity Ratio | 0% |
How did PV3B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 19:10 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EyePoint, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jennifer Kim | Cantor Fitzgerald & Co. |